Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges

The molecular chaperone Hsp90 holds great promise as a cancer drug target, despite some of the initial clinical trials of Hsp90 inhibitor drugs having not lived up to expectation. Effective use of these drugs will benefit greatly from a much more detailed understanding of the factors that contribute...

Descripción completa

Detalles Bibliográficos
Autores principales: Piper, Peter W., Millson, Stefan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060131/
https://www.ncbi.nlm.nih.gov/pubmed/27721330
http://dx.doi.org/10.3390/ph4111400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060131/
https://www.ncbi.nlm.nih.gov/pubmed/27721330
http://dx.doi.org/10.3390/ph4111400

Ejemplares similares